Beyond Your Cancer

Isoray passionately designs and develops innovative and personalized brachytherapy products that effectively treat many forms of cancer. We believe in pioneering solutions for life beyond your cancer.

Patients Treated

Isoray Medical, Inc. is an innovative company that designs and develops state-of-the-art, personalized brachytherapy products that provide a more cost-effective cancer treatment. Isoray employs approximately 40 employees, dedicated to the introduction of a unique isotope for the treatment of both common and also difficult to treat cancers.

Based in Richland, in the shadow of the Hanford Nuclear Reservation, Isoray leveraged the expertise in the region to develop a proprietary process for manufacturing a sought after new medical isotope, Cesium 131 used in brachytherapy treatment of cancer. Brachytherapy is a technique that places radiation sources (“seeds’) as close as possible to the tumor site to destroy cancer cells.

Cesium 131 has unique characteristics that have evolved into an effective treatment for many types of cancer. Specifically, Cesium 131 is able to provide a highly targeted, fast-acting radiation treatment that is able to deliver its energy in a shorter time period than conventional external beam radiation therapy or other isotopes currently used in brachytherapy, which is not only more cost-effective but typically results in less treatment side-effects.

The initial application for Cesium 131 is for the treatment of localized prostate cancer. The fast-acting nature of the treatment allows men to quickly recover from short term side-effects from radiation and return to normal urinary, bowel and sexual function faster than with other brachytherapy isotopes. A growing body of literature supports faster recovery when Cesium 131 brachytherapy is utilized.

In addition to serving as a novel, more efficient alternative for prostate brachytherapy treatment, Cesium 131 is showing great promise in other applications that previously had limited treatment alternatives, including recurrent gynecological cancers, brain tumors, sarcomas and other aggressive and recurrent tumors. Leading medical centers, hospitals and clinics across the United States are now offering this breakthrough treatment for cancer patients.

The fast-acting nature of the Cesium 131 isotope is well-suited to provide additional targeted radiation at the time of surgery, allowing for the treatment of residual disease while limiting the dose to surrounding healthy tissues. In many cases, the radiation “boost” can be delivered before conventional external beam radiation could even be started — while still delivering higher therapeutic doses.

In the case of brain cancer treatment, Isoray has submitted a 510(k) application for a novel delivery system developed in conjunction with the Barrow Neurological Institute (Phoenix, AZ) and is also pursuing a unique code to provide reimbursement.

Another exciting new application is for the treatment of recurrent gynecological tumors. Physicians at the University of Kentucky are using Cesium 131 to treat women with a less invasive approach, which historically has required extensive, debilitating surgical procedures. Early results are promising.

Isoray Medical is the sole producer of Cesium-131 brachytherapy sources, which are expanding brachytherapy treatments for difficult to treat cancers. Isoray is dedicated to pioneering cost-effective solutions for life beyond a patient’s cancer.

Investors

Review our SEC Filings, Codes of Conduct, & Management Teams.

Careers

We are always looking for talented people to join our team.

Leading Prostate Cancer Patient Advocacy in Georgia

How the Georgia Prostate Cancer Coalition is impacting the lives of >13,000 men in the state of Georgia annually. Georgia ranks #4 in the country...

Industry Insights from the 26th Annual Perspectives in Urology

Last month, industry and clinical leaders in the field of urology gathered for the 26th Annual Perspectives in Urology conference and program....

What will be shared, what will be learned at IPCU 2018?

2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet...

The Beginnings of a Brachytherapy Renaissance? Isoray’s 2017 Year In Review

Will 2017 be remembered as the beginning of a brachytherapy renaissance? While much remains to be done in clinician education and patient advocacy,...

Nasdaq Market Site Interview with Tom LaVoy, Chairman and CEO, November 26, 2017

From the Nasdaq market site in Times Square, Isoray CEO Tom Lavoy recently spoke with Jane King, LilaMax Media CEO.

Join Us at the Following Events

ASTRO

American Society for Therapeutic Radiation Oncology

September 24 – 27, 2017 San Diego Convention Center San Diego, CA

STS

Society of Thoracic Surgery

2018 Annual Meeting January 27-31, 2018 Fort Lauderdale, FL

AANS

American Association of Neurological Surgeons

April 30 - May 2, 2018 New Orleans, LA

AUA

American Urologic Association Annual Meeting 2018

May 18-22, 2018 San Francisco, CA

ABS

American Brachytherapy Society

2018 ABS Annual Meeting June 7-9, 2018 San Francisco, CA

Recent News

What will be shared, what will be learned at IPCU 2018?

2017 saw the publication and dissemination of multiple new studies, including long-term results, and guidelines for prostate cancer treatment. Yet as the year passed by, we were surprised to discover that many clinicians remained unaware of the data and its ability to...

IsoRay Announces First Quarter Fiscal 2018 Financial Results

Revenue of $1.21 Million, 12% First Quarter-Over-First Quarter Increase, Gross Margin of 22% RICHLAND, Wash., Nov. 14, 2017 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE MKT:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope...

Prostate cancer survivor Dave Ricordati: “Do your own homework.”

https://write2market.wistia.com/medias/avw40jp1hc?embedType=async&videoFoam=true&videoWidth=640 During Dave’s initial diagnosis for prostate cancer, his primary care physician and his urologist did not steer him toward brachytherapy. “Assuming you are not going to...

WKYT: “Lexington cancer doctor saving women’s lives”

Cesium-131 Brachytherapy pioneer, Dr. Jonathan Feddock was recently featured by WKYT, leading the fight against recurrent gynecologic cancer. “It's estimated every six minutes in this country, a doctor diagnoses a woman with gynecologic cancer or cancer of the...